CAM
ACOR

Capstone Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Capstone Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-108
Closed -$272K – 1615
2017
Q1 		$272K Buy
108
+7
+7% +$20.1K 0.01% 1360
2016
Q4 		$229K Sell
101
-31
-23% -$73.7K 0.01% 1496
2016
Q3 		$332K Sell
132
-2
-1% -$5.97K 0.01% 1255
2016
Q2 		$409K Buy
134
+11
+9% +$35.8K 0.01% 1083
2016
Q1 		$392K Sell
123
-2
-2% -$8.3K 0.01% 1079
2015
Q4 		$641K Buy
125
+13
+12% +$56.8K 0.02% 767
2015
Q3 		$357K Buy
112
+7
+7% +$27.1K 0.01% 1128
2015
Q2 		$420K Sell
105
-59
-36% -$228K 0.01% 1076
2015
Q1 		$654K Buy
164
+6
+4% +$27.5K 0.02% 909
2014
Q4 		$776K Sell
158
-70
-31% -$300K 0.02% 766
2014
Q3 		$927K Buy
228
+2
+0.9% +$7.5K 0.03% 615
2014
Q2 		$916K Buy
226
+27
+14% +$110K 0.03% 657
2014
Q1 		$907K Sell
199
-2
-1% -$8.09K 0.03% 663
2013
Q4 		$705K Sell
201
-11
-5% -$42.9K 0.02% 851
2013
Q3 		$869K Buy
212
+5
+2% +$21.5K 0.02% 855
2013
Q2 		$820K Buy
+207
New +$852K 0.02% 827

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capstone Asset Management's ACOR Position: Q2 2017 in Review

Capstone Asset Management sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 108 shares — an estimated $272K sold.

Capstone Asset Management first reported a position in ACOR in Q2 2013 and held it in 16 quarters. The position peaked at $927K in Q3 2014. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • Capstone Asset Management reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Capstone Asset Management sold 108 Acorda Therapeutics shares in Q2 2017, an estimated $272K.
  • Capstone Asset Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 16 quarters.
  • Capstone Asset Management's Acorda Therapeutics position peaked at $927K in Q3 2014.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.